NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98 USD | -0.01% |
|
-2.00% | -2.00% |
| 27/05 | Novartis: positive phase III results in C3G | CF |
| 27/05 | Novartis: presented results for kidney disease | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 73TCr | ||||||
| 35TCr | ||||||
| 32TCr | ||||||
| 27TCr | ||||||
| 24TCr |
